September 25, 2023

FDA grants priority review to application for Keytruda + concurrent chemoradiotherapy, as treatment for newly diagnosed high-risk locally advanced cervical cancer – Merck Inc

Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for Keytruda, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed […]

admin Health 0 1 min read
January 22, 2022

FDA approves Keytruda plus chemotherapy for cervical cancer – Merck

Merck Inc., announced that the FDA has approved Keytruda (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] at least 1) as determined by an FDA-approved test. The approval is based on the Phase III KEYNOTE-826 trial evaluating Keytruda plus […]

admin Health 0 1 min read
July 2, 2021

Merck Inc announces phase III KEYNOTE-826 trial met dual primary endpoints of overall survival and progression-free survival in patients with persistent, recurrent or metastatic cervical cancer

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read

Recent Posts

Meta

Categories

Archives

Recent Comments